Global Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Regional Outlook and Forecast, 2022 – 2028

Global Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Regional Outlook and Forecast, 2022 – 2028

The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Peptide therapeutics are polypeptides or peptides (oligomers or short polymers of amino acids) that are utilized to treat disorders. Peptide treatments replicate natural peptide functions such as hormones, neurotransmitters, growth factors, ion channel ligands, and anti-infectives. Because peptides may be digested by the body, they are thought to be reasonably safe and well-tolerated.

Liraglutide, the most popular diabetic medicine on the market, contains a lipid chain that increases plasma circulation and provides long-term absorption. Liraglutide is a GLP-1 agonist that self-assembles itself into an alpha-helical structure and only needs to be consumed once a day. Liraglutide's half-life in the blood is lengthened by approximately 13–14 hours due to lipid conjugation of a palmitoyl chain to a lysine residue at position 26. This is attributed to the palmitoyl chain's ability to bind albumin non-covalently, delaying DPP IV's proteolytic action and enabling fast renal clearance. The inclusion of the lipid chain could further extend the half-life by preventing the DPP IV enzyme from degrading sterically.

Lanreotide, an octapeptide, is another peptide that may self-assemble. This medication is a synthetic counterpart of the peptide hormone somatostatin, which is used to alleviate acromegaly (a malfunction where the body produced excessive amounts of growth hormone). Lanreotide assembles itself into monodisperse liquid crystalline nanotubes when exposed to water. The nanotubes are composed of dimers that self-assemble into a 2D lattice that is kept together by antiparallel ß-sheets and lateral chain connections. Studies on self-assembling amyloid aggregates created by peptide hormones and neuropeptides have provided more insight into how self-assembly, as well as peptide hormones, are connected.

COVID-19 Impact

COVID-19 was addressed using novel peptides that have been repurposed as medicines. Researchers throughout the world are still looking for chemicals that can either stop SARS-CoV-2 infection and replication or relieve symptoms caused by the virus. The FDA revised its definition of a biologic to include chemically produced polypeptides with a length of more than 40 amino acids but less than 100 amino acids (synthetic proteins) and synthetic peptides with a length of 40 amino acids or less (synthetic peptides). There were 21 peptide medicines in development for the treatment of COVID-19, including 15 synthetic peptides in therapies for the treatment of ARDS and other respiratory disorders caused by SARS-Cov-2 infection.

Market Growth Factors

Rising number of applications

Cardiovascular disease (CVD) is still the major cause of death and morbidity around the world. Many interventions are being tested to ameliorate pathological cardiovascular problems, however, there have been few new drugs licensed for intervention or treatment. As a result, novel techniques for treating CVD are urgently needed. The treatment of contributory risk factors and underlying mechanisms, such as inflammation, obesity, hyperglycemia, and hypercholesterolemia is frequently used to prevent vascular problems. The pharmaceutical industry has traditionally resisted using peptides as therapeutic agents due to their limited stability, size, rate of breakdown, and poor distribution. However, there has been a renaissance in the development of peptides and their synthetic derivatives for therapeutic intervention in recent years.

Increasing cases of cancer all over the world

Cancer is the second leading cause of death, accounting for a considerable number of deaths all over the world in 2013. The rate of cancer in developed countries is significantly higher than in developing countries. The prevalence of known risk factors is predicted to rise in these under-developed nations due to population growth and aging, as well as an increased prevalence of known risk factors. Lung cancer is the largest cause of death from cancer in men around the world, but only in industrialized countries, while breast cancer is the leading reason of cancer death in developing countries. Somatic gene mutations that change the function of the proteins they encode have been linked to cancer. Most solid tumors, like those of the brain, colon, breast, and pancreas, exhibit somatic changes.

Market Restraining Factors

Side effects and risks related to peptide therapy

Natural polypeptides like hormones, growth factors, and neurotransmitters, unlike synthesized peptide medications, are considered to play an important function in normal physiology. Membrane impermeability and in vivo instability are two key disadvantages of peptide medicines. Proteolytic degradation of peptide medicines in serum diminishes the bioavailable concentration and reduces the drug's half-life. To keep the medicine at a clinically effective concentration, routine dosing may be required. To avoid proteolytic degradation and enhance the in vivo half-life of peptide medicines, a variety of chemical modification approaches have been used.

Type Outlook

Based on Type, the market is segmented into Innovative and Generic. In 2021, the innovative segment procured the highest revenue share of the peptide therapeutics market. The constantly rising growth of the segment is owing to significant R&D investments by major pharmaceutical companies in the development of newer pharmaceuticals and high prescription rates. Based on kind, the market is segmented into generic and inventive categories.

Route of Administration Outlook

Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. In 2021, the pulmonary segment registered a significant revenue share of the peptide therapeutics market. The pulmonary route is recognized for peptide and protein delivery because of the physiological properties of the respiratory system. Numerous proteins and peptides are now being tested in clinical studies and are seeking authorization for use in the lungs.

Synthesis Technology Outlook

Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. In 2021, the Liquid Phase Peptide Synthesis segment recorded the highest revenue share of the peptide therapeutics market. The expediting growth of the segment is owing to the increased need for pure peptides for the development of effective medicines. Consumer preferences are evolving to quicker and more accurate approaches such as LPPS as a result of challenges such as greater time consumption. Hence, the growth of the segment is flourishing.

Type of Manufacturers Outlook

Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. In 2021, the outsourcing segment recorded a significant revenue share of the peptide therapeutics market. The growth of the segment is rising due to the challenges in developing therapeutics that meet high-quality standards. Businesses choose to outsource the Active Pharmaceutical Ingredient (API) to companies with advanced technology and expertise in the production of peptides of various sorts.

Application Outlook

Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. In 2021, the metabolic segment acquired the largest revenue share of the peptide therapeutics market. The increasing growth of the segment is attributed to the fact that metabolic problems are becoming increasingly common. These problems have become more common as a result of sedentism, bad eating habits, and excessive alcohol usage. Furthermore, the market is likely to benefit from the growing geriatric population, which is sensitive to metabolic problems.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, North America accounted for the highest revenue share of the peptide therapeutics market. The growing awareness of peptide treatments, rising demand for cancer and other disease diagnostics, and the burgeoning biotechnology industry are all contributing to the growth of the regional market. Peptide therapies are also likely to benefit from growing government R&D spending throughout the coming years. The well-established pharmaceutical and biopharmaceutical industry in this region is a primary driver of growth.

The major strategies followed by the market participants are Partnerships and Approvals. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. and Novartis AG are the forerunner in the Peptide Therapeutics Market. Companies such as Eli Lilly And Company, Sanofi S.A. and Takeda Pharmaceutical Company Limited are some of the key innovators in the Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.

Recent Strategies deployed in Peptide Therapeutics Market

Partnerships, Collaborations and Agreements:

Mar-2022: Sanofi partnered with Adagene, a platform-driven, clinical-stage biopharmaceutical company. Under this partnership, the companies would manufacture and commercialize masked monoclonal and bispecific antibodies in order to introduce transformative novel medicines to cancer patients all over the world.

Jan-2022: Amgen joined hands with Generate Biomedicinesm, a therapeutics company. Under this collaboration, the companies would focus on the discovery and development of protein therapy for five clinical targets within certain therapeutic areas as well as multiple modalities.

Dec-2021: Eli Lilly and Company came into a multi-year research collaboration and licensing agreement with Regor Therapeutics Group, a clinical-stage company. Under this agreement, the companies would discover, manufacture, and commercialize new therapies to cure metabolic disorders. Moreover, Regor's technology would also enable Eli Lilly to drive innovation and offer breakthrough therapies for diabetes and obesity.

Jul-2021: Takeda Pharmaceutical Company teamed up with PeptiDream, a biopharmaceutical company. Following this partnership, the companies would develop peptide-drug conjugates for certain central nervous system targets, which cause chronic neurodegenerative diseases.

Jul-2020: AstraZeneca entered into an agreement with Daiichi Sankyo Company, an innovative global healthcare company. Following this agreement, the companies aimed to expand the reach of the DS-1062 to more patients all over the world in a shorter period of time.

Product Launches and Product Expansions:

Apr-2020: Teva Pharmaceuticals released the autoinjector device for AJOVY. With this launch, the company aimed to offer preventive treatment for migraine to adult patients. Moreover, the new product is the only anti-CGRP preventive migraine treatment.

Acquisitions and Mergers:

May-2022: Pfizer took over Biohaven Pharmaceutical, a commercial-stage biopharmaceutical company. Following this acquisition, the company aimed to incorporate Biohaven's Rimegepant and Zavegepant along with an offering of five pre-clinical CGRP assets.

Jul-2021: Eli Lilly and Company completed its acquisition of Protomer Technologies, a biotech company. With this acquisition, the company aimed to integrate the glucose-sensing insulin program of Protomer Technologies into its portfolio in order to strengthen its offerings. In addition, Eli Lilly would enhance the diabetes lineup of Protomer with the company's innovative technology

Sep-2020: AstraZeneca acquired the preclinical oral PCSK9 inhibitor program of Dogma Therapeutics, an operator of a biotechnology platform. Following this acquisition, the company aimed to advance the program into the clinical development for dyslipidemia and familial hypercholesterolemia.

Approvals and Trails:

May-2022: Eli Lilly and Company received the US FDA approval for its Mounjaro injection. The novel once-weekly GIP and GLP-1 receptors agonist are approved as an adjunct to exercise and diet in order to enhance glycemic control within adults with type 2 diabetes.

Mar-2022: Novartis received the US FDA approval for its Pluvicto. Through this approval, the company aimed to offer a treatment to adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer, a type of advanced cancer. In addition, Pluvicto is the first radioligand therapy approved by the US FDA that incorporates a therapeutic radioisotope and a targeting compound.

Sep-2021: Teva Pharmaceuticals and MedinCell received the US FDA approval for their TV-46000/mdc-IRM. The new product is approved on the basis of the RISE Study and SHINE Study, two Phase III clinical trials, for the treatment of schizophrenia.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Innovative
  • Generic
By Route of Administration
  • Parenteral Route
  • Pulmonary
  • Mucosal
  • Oral Route
  • Others
By Synthesis Technology
  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid Technology
By Type of Manufacturers
  • In-house
  • Outsourced
By Application
  • Metabolic
  • Cardiovascular Disorder
  • GIT & Renal
  • Antiinfection & Dermatology
  • Respiratory
  • Central Nervous System
  • Cancer
  • Pain
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Eli Lilly And Company
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Lonza Group AG
  • Amgen, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.1 Objectives
1.2 Market Scope
1.3 Segmentation
1.3.1 Global Peptide Therapeutics Market, by Type
1.3.2 Global Peptide Therapeutics Market, by Route of Administration
1.3.3 Global Peptide Therapeutics Market, by Synthesis Technology
1.3.4 Global Peptide Therapeutics Market, by Type of Manufacturers
1.3.5 Global Peptide Therapeutics Market, by Application
1.3.6 Global Peptide Therapeutics Market, by Geography
1.4 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trails
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Global Peptide Therapeutics Market by Type
4.1 Global Innovative Market by Region
4.2 Global Generic Market by Region
Chapter 5. Global Peptide Therapeutics Market by Route of Administration
5.1 Global Parenteral Route Market by Region
5.2 Global Pulmonary Market by Region
5.3 Global Mucosal Market by Region
5.4 Global Oral Route Market by Region
5.5 Global Others Market by Region
Chapter 6. Global Peptide Therapeutics Market by Synthesis Technology
6.1 Global Liquid Phase Peptide Synthesis (LPPS) Market by Region
6.2 Global Solid Phase Peptide Synthesis (SPPS) Market by Region
6.3 Global Hybrid Technology Market by Region
Chapter 7. Global Peptide Therapeutics Market by Type of Manufacturers
7.1 Global In-house Market by Region
7.2 Global Outsourced Market by Region
Chapter 8. Global Peptide Therapeutics Market by Application
8.1 Global Metabolic Market by Region
8.2 Global Cardiovascular Disorder Market by Region
8.3 Global GIT & Renal Market by Region
8.4 Global Antiinfection & Dermatology Market by Region
8.5 Global Respiratory Market by Region
8.6 Global Central Nervous System Market by Region
8.7 Global Cancer Market by Region
8.8 Global Pain Market by Region
8.9 Global Others Market by Region
Chapter 9. Global Peptide Therapeutics Market by Region
9.1 North America Peptide Therapeutics Market
9.1.1 North America Peptide Therapeutics Market by Type
9.1.1.1 North America Innovative Market by Country
9.1.1.2 North America Generic Market by Country
9.1.2 North America Peptide Therapeutics Market by Route of Administration
9.1.2.1 North America Parenteral Route Market by Country
9.1.2.2 North America Pulmonary Market by Country
9.1.2.3 North America Mucosal Market by Country
9.1.2.4 North America Oral Route Market by Country
9.1.2.5 North America Others Market by Country
9.1.3 North America Peptide Therapeutics Market by Synthesis Technology
9.1.3.1 North America Liquid Phase Peptide Synthesis (LPPS) Market by Country
9.1.3.2 North America Solid Phase Peptide Synthesis (SPPS) Market by Country
9.1.3.3 North America Hybrid Technology Market by Country
9.1.4 North America Peptide Therapeutics Market by Type of Manufacturers
9.1.4.1 North America In-house Market by Country
9.1.4.2 North America Outsourced Market by Country
9.1.5 North America Peptide Therapeutics Market by Application
9.1.5.1 North America Metabolic Market by Country
9.1.5.2 North America Cardiovascular Disorder Market by Country
9.1.5.3 North America GIT & Renal Market by Country
9.1.5.4 North America Antiinfection & Dermatology Market by Country
9.1.5.5 North America Respiratory Market by Country
9.1.5.6 North America Central Nervous System Market by Country
9.1.5.7 North America Cancer Market by Country
9.1.5.8 North America Pain Market by Country
9.1.5.9 North America Others Market by Country
9.1.6 North America Peptide Therapeutics Market by Country
9.1.6.1 US Peptide Therapeutics Market
9.1.6.1.1 US Peptide Therapeutics Market by Type
9.1.6.1.2 US Peptide Therapeutics Market by Route of Administration
9.1.6.1.3 US Peptide Therapeutics Market by Synthesis Technology
9.1.6.1.4 US Peptide Therapeutics Market by Type of Manufacturers
9.1.6.1.5 US Peptide Therapeutics Market by Application
9.1.6.2 Canada Peptide Therapeutics Market
9.1.6.2.1 Canada Peptide Therapeutics Market by Type
9.1.6.2.2 Canada Peptide Therapeutics Market by Route of Administration
9.1.6.2.3 Canada Peptide Therapeutics Market by Synthesis Technology
9.1.6.2.4 Canada Peptide Therapeutics Market by Type of Manufacturers
9.1.6.2.5 Canada Peptide Therapeutics Market by Application
9.1.6.3 Mexico Peptide Therapeutics Market
9.1.6.3.1 Mexico Peptide Therapeutics Market by Type
9.1.6.3.2 Mexico Peptide Therapeutics Market by Route of Administration
9.1.6.3.3 Mexico Peptide Therapeutics Market by Synthesis Technology
9.1.6.3.4 Mexico Peptide Therapeutics Market by Type of Manufacturers
9.1.6.3.5 Mexico Peptide Therapeutics Market by Application
9.1.6.4 Rest of North America Peptide Therapeutics Market
9.1.6.4.1 Rest of North America Peptide Therapeutics Market by Type
9.1.6.4.2 Rest of North America Peptide Therapeutics Market by Route of Administration
9.1.6.4.3 Rest of North America Peptide Therapeutics Market by Synthesis Technology
9.1.6.4.4 Rest of North America Peptide Therapeutics Market by Type of Manufacturers
9.1.6.4.5 Rest of North America Peptide Therapeutics Market by Application
9.2 Europe Peptide Therapeutics Market
9.2.1 Europe Peptide Therapeutics Market by Type
9.2.1.1 Europe Innovative Market by Country
9.2.1.2 Europe Generic Market by Country
9.2.2 Europe Peptide Therapeutics Market by Route of Administration
9.2.2.1 Europe Parenteral Route Market by Country
9.2.2.2 Europe Pulmonary Market by Country
9.2.2.3 Europe Mucosal Market by Country
9.2.2.4 Europe Oral Route Market by Country
9.2.2.5 Europe Others Market by Country
9.2.3 Europe Peptide Therapeutics Market by Synthesis Technology
9.2.3.1 Europe Liquid Phase Peptide Synthesis (LPPS) Market by Country
9.2.3.2 Europe Solid Phase Peptide Synthesis (SPPS) Market by Country
9.2.3.3 Europe Hybrid Technology Market by Country
9.2.4 Europe Peptide Therapeutics Market by Type of Manufacturers
9.2.4.1 Europe In-house Market by Country
9.2.4.2 Europe Outsourced Market by Country
9.2.5 Europe Peptide Therapeutics Market by Application
9.2.5.1 Europe Metabolic Market by Country
9.2.5.2 Europe Cardiovascular Disorder Market by Country
9.2.5.3 Europe GIT & Renal Market by Country
9.2.5.4 Europe Antiinfection & Dermatology Market by Country
9.2.5.5 Europe Respiratory Market by Country
9.2.5.6 Europe Central Nervous System Market by Country
9.2.5.7 Europe Cancer Market by Country
9.2.5.8 Europe Pain Market by Country
9.2.5.9 Europe Others Market by Country
9.2.6 Europe Peptide Therapeutics Market by Country
9.2.6.1 Germany Peptide Therapeutics Market
9.2.6.1.1 Germany Peptide Therapeutics Market by Type
9.2.6.1.2 Germany Peptide Therapeutics Market by Route of Administration
9.2.6.1.3 Germany Peptide Therapeutics Market by Synthesis Technology
9.2.6.1.4 Germany Peptide Therapeutics Market by Type of Manufacturers
9.2.6.1.5 Germany Peptide Therapeutics Market by Application
9.2.6.2 UK Peptide Therapeutics Market
9.2.6.2.1 UK Peptide Therapeutics Market by Type
9.2.6.2.2 UK Peptide Therapeutics Market by Route of Administration
9.2.6.2.3 UK Peptide Therapeutics Market by Synthesis Technology
9.2.6.2.4 UK Peptide Therapeutics Market by Type of Manufacturers
9.2.6.2.5 UK Peptide Therapeutics Market by Application
9.2.6.3 France Peptide Therapeutics Market
9.2.6.3.1 France Peptide Therapeutics Market by Type
9.2.6.3.2 France Peptide Therapeutics Market by Route of Administration
9.2.6.3.3 France Peptide Therapeutics Market by Synthesis Technology
9.2.6.3.4 France Peptide Therapeutics Market by Type of Manufacturers
9.2.6.3.5 France Peptide Therapeutics Market by Application
9.2.6.4 Russia Peptide Therapeutics Market
9.2.6.4.1 Russia Peptide Therapeutics Market by Type
9.2.6.4.2 Russia Peptide Therapeutics Market by Route of Administration
9.2.6.4.3 Russia Peptide Therapeutics Market by Synthesis Technology
9.2.6.4.4 Russia Peptide Therapeutics Market by Type of Manufacturers
9.2.6.4.5 Russia Peptide Therapeutics Market by Application
9.2.6.5 Spain Peptide Therapeutics Market
9.2.6.5.1 Spain Peptide Therapeutics Market by Type
9.2.6.5.2 Spain Peptide Therapeutics Market by Route of Administration
9.2.6.5.3 Spain Peptide Therapeutics Market by Synthesis Technology
9.2.6.5.4 Spain Peptide Therapeutics Market by Type of Manufacturers
9.2.6.5.5 Spain Peptide Therapeutics Market by Application
9.2.6.6 Italy Peptide Therapeutics Market
9.2.6.6.1 Italy Peptide Therapeutics Market by Type
9.2.6.6.2 Italy Peptide Therapeutics Market by Route of Administration
9.2.6.6.3 Italy Peptide Therapeutics Market by Synthesis Technology
9.2.6.6.4 Italy Peptide Therapeutics Market by Type of Manufacturers
9.2.6.6.5 Italy Peptide Therapeutics Market by Application
9.2.6.7 Rest of Europe Peptide Therapeutics Market
9.2.6.7.1 Rest of Europe Peptide Therapeutics Market by Type
9.2.6.7.2 Rest of Europe Peptide Therapeutics Market by Route of Administration
9.2.6.7.3 Rest of Europe Peptide Therapeutics Market by Synthesis Technology
9.2.6.7.4 Rest of Europe Peptide Therapeutics Market by Type of Manufacturers
9.2.6.7.5 Rest of Europe Peptide Therapeutics Market by Application
9.3 Asia Pacific Peptide Therapeutics Market
9.3.1 Asia Pacific Peptide Therapeutics Market by Type
9.3.1.1 Asia Pacific Innovative Market by Country
9.3.1.2 Asia Pacific Generic Market by Country
9.3.2 Asia Pacific Peptide Therapeutics Market by Route of Administration
9.3.2.1 Asia Pacific Parenteral Route Market by Country
9.3.2.2 Asia Pacific Pulmonary Market by Country
9.3.2.3 Asia Pacific Mucosal Market by Country
9.3.2.4 Asia Pacific Oral Route Market by Country
9.3.2.5 Asia Pacific Others Market by Country
9.3.3 Asia Pacific Peptide Therapeutics Market by Synthesis Technology
9.3.3.1 Asia Pacific Liquid Phase Peptide Synthesis (LPPS) Market by Country
9.3.3.2 Asia Pacific Solid Phase Peptide Synthesis (SPPS) Market by Country
9.3.3.3 Asia Pacific Hybrid Technology Market by Country
9.3.4 Asia Pacific Peptide Therapeutics Market by Type of Manufacturers
9.3.4.1 Asia Pacific In-house Market by Country
9.3.4.2 Asia Pacific Outsourced Market by Country
9.3.5 Asia Pacific Peptide Therapeutics Market by Application
9.3.5.1 Asia Pacific Metabolic Market by Country
9.3.5.2 Asia Pacific Cardiovascular Disorder Market by Country
9.3.5.3 Asia Pacific GIT & Renal Market by Country
9.3.5.4 Asia Pacific Antiinfection & Dermatology Market by Country
9.3.5.5 Asia Pacific Respiratory Market by Country
9.3.5.6 Asia Pacific Central Nervous System Market by Country
9.3.5.7 Asia Pacific Cancer Market by Country
9.3.5.8 Asia Pacific Pain Market by Country
9.3.5.9 Asia Pacific Others Market by Country
9.3.6 Asia Pacific Peptide Therapeutics Market by Country
9.3.6.1 China Peptide Therapeutics Market
9.3.6.1.1 China Peptide Therapeutics Market by Type
9.3.6.1.2 China Peptide Therapeutics Market by Route of Administration
9.3.6.1.3 China Peptide Therapeutics Market by Synthesis Technology
9.3.6.1.4 China Peptide Therapeutics Market by Type of Manufacturers
9.3.6.1.5 China Peptide Therapeutics Market by Application
9.3.6.2 Japan Peptide Therapeutics Market
9.3.6.2.1 Japan Peptide Therapeutics Market by Type
9.3.6.2.2 Japan Peptide Therapeutics Market by Route of Administration
9.3.6.2.3 Japan Peptide Therapeutics Market by Synthesis Technology
9.3.6.2.4 Japan Peptide Therapeutics Market by Type of Manufacturers
9.3.6.2.5 Japan Peptide Therapeutics Market by Application
9.3.6.3 India Peptide Therapeutics Market
9.3.6.3.1 India Peptide Therapeutics Market by Type
9.3.6.3.2 India Peptide Therapeutics Market by Route of Administration
9.3.6.3.3 India Peptide Therapeutics Market by Synthesis Technology
9.3.6.3.4 India Peptide Therapeutics Market by Type of Manufacturers
9.3.6.3.5 India Peptide Therapeutics Market by Application
9.3.6.4 South Korea Peptide Therapeutics Market
9.3.6.4.1 South Korea Peptide Therapeutics Market by Type
9.3.6.4.2 South Korea Peptide Therapeutics Market by Route of Administration
9.3.6.4.3 South Korea Peptide Therapeutics Market by Synthesis Technology
9.3.6.4.4 South Korea Peptide Therapeutics Market by Type of Manufacturers
9.3.6.4.5 South Korea Peptide Therapeutics Market by Application
9.3.6.5 Singapore Peptide Therapeutics Market
9.3.6.5.1 Singapore Peptide Therapeutics Market by Type
9.3.6.5.2 Singapore Peptide Therapeutics Market by Route of Administration
9.3.6.5.3 Singapore Peptide Therapeutics Market by Synthesis Technology
9.3.6.5.4 Singapore Peptide Therapeutics Market by Type of Manufacturers
9.3.6.5.5 Singapore Peptide Therapeutics Market by Application
9.3.6.6 Malaysia Peptide Therapeutics Market
9.3.6.6.1 Malaysia Peptide Therapeutics Market by Type
9.3.6.6.2 Malaysia Peptide Therapeutics Market by Route of Administration
9.3.6.6.3 Malaysia Peptide Therapeutics Market by Synthesis Technology
9.3.6.6.4 Malaysia Peptide Therapeutics Market by Type of Manufacturers
9.3.6.6.5 Malaysia Peptide Therapeutics Market by Application
9.3.6.7 Rest of Asia Pacific Peptide Therapeutics Market
9.3.6.7.1 Rest of Asia Pacific Peptide Therapeutics Market by Type
9.3.6.7.2 Rest of Asia Pacific Peptide Therapeutics Market by Route of Administration
9.3.6.7.3 Rest of Asia Pacific Peptide Therapeutics Market by Synthesis Technology
9.3.6.7.4 Rest of Asia Pacific Peptide Therapeutics Market by Type of Manufacturers
9.3.6.7.5 Rest of Asia Pacific Peptide Therapeutics Market by Application
9.4 LAMEA Peptide Therapeutics Market
9.4.1 LAMEA Peptide Therapeutics Market by Type
9.4.1.1 LAMEA Innovative Market by Country
9.4.1.2 LAMEA Generic Market by Country
9.4.2 LAMEA Peptide Therapeutics Market by Route of Administration
9.4.2.1 LAMEA Parenteral Route Market by Country
9.4.2.2 LAMEA Pulmonary Market by Country
9.4.2.3 LAMEA Mucosal Market by Country
9.4.2.4 LAMEA Oral Route Market by Country
9.4.2.5 LAMEA Others Market by Country
9.4.3 LAMEA Peptide Therapeutics Market by Synthesis Technology
9.4.3.1 LAMEA Liquid Phase Peptide Synthesis (LPPS) Market by Country
9.4.3.2 LAMEA Solid Phase Peptide Synthesis (SPPS) Market by Country
9.4.3.3 LAMEA Hybrid Technology Market by Country
9.4.4 LAMEA Peptide Therapeutics Market by Type of Manufacturers
9.4.4.1 LAMEA In-house Market by Country
9.4.4.2 LAMEA Outsourced Market by Country
9.4.5 LAMEA Peptide Therapeutics Market by Application
9.4.5.1 LAMEA Metabolic Market by Country
9.4.5.2 LAMEA Cardiovascular Disorder Market by Country
9.4.5.3 LAMEA GIT & Renal Market by Country
9.4.5.4 LAMEA Antiinfection & Dermatology Market by Country
9.4.5.5 LAMEA Respiratory Market by Country
9.4.5.6 LAMEA Central Nervous System Market by Country
9.4.5.7 LAMEA Cancer Market by Country
9.4.5.8 LAMEA Pain Market by Country
9.4.5.9 LAMEA Others Market by Country
9.4.6 LAMEA Peptide Therapeutics Market by Country
9.4.6.1 Brazil Peptide Therapeutics Market
9.4.6.1.1 Brazil Peptide Therapeutics Market by Type
9.4.6.1.2 Brazil Peptide Therapeutics Market by Route of Administration
9.4.6.1.3 Brazil Peptide Therapeutics Market by Synthesis Technology
9.4.6.1.4 Brazil Peptide Therapeutics Market by Type of Manufacturers
9.4.6.1.5 Brazil Peptide Therapeutics Market by Application
9.4.6.2 Argentina Peptide Therapeutics Market
9.4.6.2.1 Argentina Peptide Therapeutics Market by Type
9.4.6.2.2 Argentina Peptide Therapeutics Market by Route of Administration
9.4.6.2.3 Argentina Peptide Therapeutics Market by Synthesis Technology
9.4.6.2.4 Argentina Peptide Therapeutics Market by Type of Manufacturers
9.4.6.2.5 Argentina Peptide Therapeutics Market by Application
9.4.6.3 UAE Peptide Therapeutics Market
9.4.6.3.1 UAE Peptide Therapeutics Market by Type
9.4.6.3.2 UAE Peptide Therapeutics Market by Route of Administration
9.4.6.3.3 UAE Peptide Therapeutics Market by Synthesis Technology
9.4.6.3.4 UAE Peptide Therapeutics Market by Type of Manufacturers
9.4.6.3.5 UAE Peptide Therapeutics Market by Application
9.4.6.4 Saudi Arabia Peptide Therapeutics Market
9.4.6.4.1 Saudi Arabia Peptide Therapeutics Market by Type
9.4.6.4.2 Saudi Arabia Peptide Therapeutics Market by Route of Administration
9.4.6.4.3 Saudi Arabia Peptide Therapeutics Market by Synthesis Technology
9.4.6.4.4 Saudi Arabia Peptide Therapeutics Market by Type of Manufacturers
9.4.6.4.5 Saudi Arabia Peptide Therapeutics Market by Application
9.4.6.5 South Africa Peptide Therapeutics Market
9.4.6.5.1 South Africa Peptide Therapeutics Market by Type
9.4.6.5.2 South Africa Peptide Therapeutics Market by Route of Administration
9.4.6.5.3 South Africa Peptide Therapeutics Market by Synthesis Technology
9.4.6.5.4 South Africa Peptide Therapeutics Market by Type of Manufacturers
9.4.6.5.5 South Africa Peptide Therapeutics Market by Application
9.4.6.6 Nigeria Peptide Therapeutics Market
9.4.6.6.1 Nigeria Peptide Therapeutics Market by Type
9.4.6.6.2 Nigeria Peptide Therapeutics Market by Route of Administration
9.4.6.6.3 Nigeria Peptide Therapeutics Market by Synthesis Technology
9.4.6.6.4 Nigeria Peptide Therapeutics Market by Type of Manufacturers
9.4.6.6.5 Nigeria Peptide Therapeutics Market by Application
9.4.6.7 Rest of LAMEA Peptide Therapeutics Market
9.4.6.7.1 Rest of LAMEA Peptide Therapeutics Market by Type
9.4.6.7.2 Rest of LAMEA Peptide Therapeutics Market by Route of Administration
9.4.6.7.3 Rest of LAMEA Peptide Therapeutics Market by Synthesis Technology
9.4.6.7.4 Rest of LAMEA Peptide Therapeutics Market by Type of Manufacturers
9.4.6.7.5 Rest of LAMEA Peptide Therapeutics Market by Application
Chapter 10. Company Profiles
10.1 Eli Lilly And Company
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.1.5.2 Acquisition and Mergers:
10.1.5.3 Approvals and Trails:
10.2 AstraZeneca PLC
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expenses
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.2.5.2 Acquisition and Mergers:
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expenses
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals and Acquisitions:
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Acquisition and Mergers:
10.4.5.2 Approvals and Trails:
10.5 Pfizer, Inc.
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional & Segmental Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Acquisition and Mergers:
10.6 Sanofi S.A.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 GlaxoSmithKline PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.8 Takeda Pharmaceutical Company Limited
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expense
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals and Trails:
10.9 Lonza Group AG
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Segmental and Regional Analysis
10.9.4 Research & Development Expenses
10.10. Amgen, Inc.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Partnerships, Collaborations, and Agreements:

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings